TSR 042

Drug Profile

TSR 042

Alternative Names: ANB 011; Anti-PD-1 mAb; Anti-PD-1 monospecific antagonist antibody; TSR-042

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AnaptysBio
  • Developer TESARO
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Endometrial cancer; Solid tumours

Most Recent Events

  • 08 Aug 2017 Clinical trials in Solid tumours (Combination therapy) (Parenteral)
  • 03 Jun 2017 Safety and efficacy data from a phase I trial in Solid tumours released by TESARO
  • 03 Jun 2017 TESARO completes the dose escalation part of phase I trial in Solid tumours (Metastatic disease, Second-line therapy or greater) in USA, United Kingdom, Spain, Poland, Italy, France, Czech Republic and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top